XU Bailing
Principal Investigator
Xu Bailing, professor, Ph.D. supervisor, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College. Xu received Ph.D. degree in medicinal chemistry from the Institute of Material Medica in 1998. In the same year, she joined the IMM of PUMC as an assistant professor. During 2001-2004, she worked as postdoctoral fellow at the Cancer Center of University of San Francisco and Virginia Tech., respectively. Since the year of 2004, she has been working at the Institute of Materia Medica as a principal investigator in the area of medicinal chemistry. Currently, the main research interests of her team focus on developing structurally diverse small molecules as anticancer, anti-diabetes and anti-psychotic drug candidates on the basis of receptor-based and/or ligand-based molecular design.
1. Design, synthesis and biological evaluation of novel thiazole-based derivatives as human Pin1 inhibitors. Bioorganic & Medicinal Chemistry , 2021, 29: 115878-115891.
2. Discovery of N-arylsulfonyl-indole-2-carboxamide derivatives as potent, selective, and orally bioavailable fructose-1,6-bisphosphatase inhibitors― design, synthesis, in vivo glucose lowering effects, and X-ray crystal complex analysis. Journal of Medicinal Chemistry , 2020, 63, 10307-10329.
3. Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors. European Journal of Medicinal Chemistry , 2020,188: 111985-112005
4. Discovery of quinazoline-2,4(1H,3H)-dione derivatives as novel PARP1/2 inhibitors: design,synthesis and their antitumor activity. Organic & Biomolecilar Chemistry , 2018, 16(17):3189-3202.
5. Synthesis and biological evaluation of pyrimidine derivatives as novel Pin1 inhibitors. Bioorganic & Medicinal Chemistry , 2018, 26(8): 2186-2197.
6. Discovery of 2-substituted 1H-benzo[d]imidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in vivo anti-tumor activity. European Journal of Medicinal Chemistry , 2017,132: 26-41.
7. Discovery of novel quinazoline-2,4(1H,3H)-dione derivatives as potent PARP-2 selective inhibitors. Bioorgnic Medicinal Chemistry , 2017, 25(15): 4045-4054.
8. Synthesis and Pin1 inhibitory activity of thiazole derivatives. Bioorgnic Medicinal Chemistry , 2016, 24, 5911-5920.
9. Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors. Bioorgnic Medicinal Chemistry , 2015, 23, 681-693.
10. Discovery of novel indole derivatives as allosteric inhibitors of fructose-1, 6-bisphosphatase. European Journal of Medicinal Chemistry , 2015, 90, 394-405.
11. Design, synthesis and biological evaluation of 7-nitro-1H-indole-2-carboxylic acid derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase. Bioorgnic Medicinal Chemistry , 2014, 22, 1850-1862.
12. Synthesis and biological evaluation of novel quinoxalinone-based HIV-1 reverse transcriptase inhibitors. Med. Chem. Commun. , 2014, 5, 441-444.
13. Synthesis and antiproliferative evaluation of novel benzoimidazole-contained oxazole-bridged analogs of combretastatin A-4. European Journal of Medicinal Chemistry , 2013, 68, 222-232.
14. Synthesis and biological evaluation of novel human Pin1 inhibitors with benzophenone skeleton. Bioorg. Med. Chem. , 2012, 20, 2992-2999.
